Evidence map›Paper›PMID 29276005›Full record

ArticleAmerican journal of human genetics2018

Histone Lysine Methylases and Demethylases in the Landscape of Human Developmental Disorders.

Víctor Faundes, William G Newman, Laura Bernardini, Natalie Canham, Jill Clayton-Smith, Bruno Dallapiccola, Sally J Davies, Michelle K Demos, Amy Goldman, Harinder Gill and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed, 5 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

182 citing papers in PubMed, 5 syntheses or guidelines pooled it, 271 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Variable Expressiveness of a Novel PathogenicDiseases (Basel, Switzerland) · 2026
    Article
  9. Article
  10. Article
  11. Ultra-low oxygen tension duringbioRxiv : the preprint server for biology · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

122 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 16 institutions in 4 countries.

Víctor FaundesManchester Centre for Genomic Medicine, Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9WL, UK; Laboratorio de Genética y Enfermedades Metabólicas, Instituto de Nutrición y Tecnología de los Alimentos , Universidad de Chile, Santiago 7830490, Chile.
William G NewmanManchester Centre for Genomic Medicine, Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9WL, UK; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester M13 9WL, UK.
Laura BernardiniCytogenetics Unit, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo FG 71013, Italy.
Natalie CanhamNorth West Thames Regional Genetics Service, London North West Healthcare NHS Trust, Northwick Park Hospital, Watford Road, Harrow HA1 3UJ, UK.
Jill Clayton-SmithManchester Centre for Genomic Medicine, Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9WL, UK; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester M13 9WL, UK.
Bruno DallapiccolaScientific Directorate, Bambino Gesù Children's Hospital, IRCCS, Rome 00146, Italy.
Sally J DaviesInstitute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK.
Michelle K DemosDivision of Pediatric Neurology, Department of Pediatrics, University of British Columbia, Vancouver, BC V6H 3V4, Canada.
Amy GoldmanManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester M13 9WL, UK.
Harinder GillDepartment of Medical Genetics, Children's and Women's Health Centre of British Columbia, Vancouver, BC V6H 3N1, Canada.
Rachel HortonWessex Clinical Genetics Service and Division of Human Genetics, Princess Anne Hospital, Southampton SO16 5YA, UK.
Bronwyn KerrManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester M13 9WL, UK.
Dhavendra KumarInstitute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK.
Anna LehmanDepartment of Medical Genetics, Children's and Women's Health Centre of British Columbia, Vancouver, BC V6H 3N1, Canada.
Shane McKeeNorthern Ireland Regional Genetics Service, Belfast City Hospital, Belfast HSC Trust, Belfast BT9 7AB, UK.
Jenny MortonWest Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham B15 2TG, UK.
Michael J ParkerSheffield Clinical Genetics Service, Sheffield Children's Hospital NHS Foundation Trust, Western Bank, Sheffield S10 2TH, UK.
Julia RankinPeninsula Clinical Genetics Service, Exeter EX1 2ED, UK.
Lisa RobertsonNorth of Scotland Regional Genetics Service, NHS Grampian, Department of Medical Genetics Medical School, Foresterhill, Aberdeen, AB25 2ZD, UK.
I Karen TempleWessex Clinical Genetics Service and Division of Human Genetics, Princess Anne Hospital, Southampton SO16 5YA, UK.
Clinical Assessment of the Utility of Sequencing and Evaluation as a Service (CAUSES) StudyDepartment of Medical Genetics, Children's and Women's Health Centre of British Columbia, Vancouver, BC V6H 3N1, Canada.
Deciphering Developmental Disorders (DDD) StudyWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK.
Siddharth BankaManchester Centre for Genomic Medicine, Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9WL, UK; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester M13 9WL, UK. Electronic address: siddharth.banka@manchester.ac.uk.
University of Manchester · GBChildren's & Women's Health Centre of British Columbia · CAUniversity Hospital of Wales · GBNHS Grampian · GBSheffield Children's Hospital · GBPrincess Anne Hospital · GBSt Mary's Hospital · GBBirmingham Women’s and Children’s NHS Foundation Trust · GBLondon North West Healthcare NHS Trust · GBManchester Academic Health Science Centre · GBPeninsula College of Medicine and Dentistry · GBUniversity of Ulster · GBCasa Sollievo della Sofferenza · ITWellcome Sanger Institute · GBBambino Gesù Children's Hospital · ITUniversity of British Columbia · CA

Funding

Wellcome Trust
6 · The paper itself

Abstract

Histone lysine methyltransferases (KMTs) and demethylases (KDMs) underpin gene regulation. Here we demonstrate that variants causing haploinsufficiency of KMTs and KDMs are frequently encountered in individuals with developmental disorders. Using a combination of human variation databases and existing animal models, we determine 22 KMTs and KDMs as additional candidates for dominantly inherited developmental disorders. We show that KMTs and KDMs that are associated with, or are candidates for, dominant developmental disorders tend to have a higher level of transcription, longer canonical transcripts, more interactors, and a higher number and more types of post-translational modifications than other KMT and KDMs. We provide evidence to firmly associate KMT2C, ASH1L, and KMT5B haploinsufficiency with dominant developmental disorders. Whereas KMT2C or ASH1L haploinsufficiency results in a predominantly neurodevelopmental phenotype with occasional physical anomalies, KMT5B mutations cause an overgrowth syndrome with intellectual disability. We further expand the phenotypic spectrum of KMT2B-related disorders and show that some individuals can have severe developmental delay without dystonia at least until mid-childhood. Additionally, we describe a recessive histone lysine-methylation defect caused by homozygous or compound heterozygous KDM5B variants and resulting in a recognizable syndrome with developmental delay, facial dysmorphism, and camptodactyly. Collectively, these results emphasize the significance of histone lysine methylation in normal human development and the importance of this process in human developmental disorders. Our results demonstrate that systematic clinically oriented pathway-based analysis of genomic data can accelerate the discovery of rare genetic disorders.

Indexed as

AdolescentChildChild, PreschoolDevelopmental DisabilitiesFemaleHaploinsufficiencyHistone DemethylasesHistone-Lysine N-MethyltransferaseHumansMaleMutationHistone DemethylasesHistone-Lysine N-MethyltransferaseASH1Lchromatin remodelingDevelopmental disordershistone lysine demethylasehistone lysine methyltransferaseKDM5BKMT2BKMT2CKMT5B

Identifiers

PMID29276005
PMCPMC5778085
OpenAlexW2778047690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.